X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Search Again

We support boolean queries, use +,-,<,>,~,* to alter the weighting of terms

Showing 20 out of 29,142 Resources on page 1269

Amorfix

Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

Onyx Pharmaceuticals

November 2020, Onyx merged with Legacy Acquisition Corp. to form PARTS iD, Inc. Our data intelligence, integrated platforms, product cataloging, digital marketing expertise, and virtual warehousing have ensured our continued leadership in the competitive marketplace.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

PatientsLikeMe

A for-profit health data-sharing platform that can transform the way patients manage their conditions, change the way industry conducts research and improve patient care. PatientsLikeMe aligns patient and industry interests through data-sharing partnerships. They work with trusted nonprofit, research and industry Partners who use this health data to improve products, services and care for patients. They take the information patients share about their experience with the disease and sell it to their partners (i.e., companies that are developing or selling products to patients). These products may include drugs, devices, equipment, insurance, and medical services. Except for the restricted personal information entered when registering for the site, participants should expect that every piece of information submitted (even if it is not currently displayed) may be shared with their partners and any member of PatientsLikeMe, including other patients. They do not rent, sell or share personally identifiable information for marketing purposes or without explicit consent. Because they believe in transparency, they tell members exactly what they do and do not do with their data. Patients have the opportunity to share both personal stories and health data about their conditions to help uncover great ideas and new knowledge. By sharing information on the site, they can put their disease experiences in context and find answers to the questions they have. Every partnership we develop must bring them closer to aligning patient and industry interests. Their end goal is improved patient care and quality of life.

  • Resource
  • SciCrunch
  • 16 years ago - by Anonymous

Sciencewise

Sciencewise-ERC is the UK's national center for public dialogue in policy making involving science and technology issues. It provides co-funding and specialist advice and support to Government departments and agencies to develop and commission public dialogue activities in emerging areas of science and technology. It consists of a comprehensive online resource of information, advice and guidance together with a wide range of support services aimed at policy makers and all the different stakeholders involved in science and technology policy making, including the public. Sciencewise-ERC works with central Government and its agencies, and executive, advisory and non-departmental public bodies. Some of the Government departments include the Department for Environment, Food and Rural Affairs (Defra), the Department of Energy and Climate Change (DECC) and most recently HM Treasury.

  • Resource
  • SciCrunch
  • 16 years ago - by Anonymous

Neuroflocks - tweets from SfN2010

Neuroflocks is an unique tool to navigate tweets from the past SfN meeting and find out the hot topics tweeted during the conference (SfN-2010). We have collected all tweets using the hashtag #sfn10 and made them browsable via a simple visual search interface. Type in the word you want to search for and only tweets containing that word will light up! You can click on single tweets, browse the tweet content, click on the Twitter user and find new Neuroscience-enthusiast twitterers! You can also find out what was really HOT during the conference (Re-Tweeted tweets, RT have been color coded). Moreover, the tweets follow a time gradient from the inside out: the spiral's center contains tweets from the beginning of the meeting while tweets on the outside of the spiral were tweeted at the end of the meeting. Enhanced versions of neuroflocks are currently under development !!!

  • Resource
  • SciCrunch
  • 15 years ago - by Anonymous

Plant Metabolic Network

Collaborative project to bring together biochemical pathway databases and research communities focused on plant metabolism. Used to build broad network of plant metabolic pathway databases. Central feature of PMN is PlantCyc, comprehensive plant biochemical pathway database, containing curated information from literature and computational analyses about genes, enzymes, compounds, reactions, and pathways involved in primary and secondary metabolism.

  • Resource
  • SciCrunch
  • 16 years ago - by Anonymous

MIAPA

Central hub for resources related to developing and deploying a Minimal Information for a Phylogenetic Analysis (MIAPA) standard.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

PEAR

Software for an ultrafast, memory-efficient and highly accurate pair-end read merger. It is fully parallelized and can run with as low as just a few kilobytes of memory.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

Lhasa Limited

A not-for-profit membership organization and educational charity that facilitates collaborative data sharing projects in the pharmaceutical, cosmetics and chemistry-related industries specializing in the development of expert computer systems for toxicity and metabolism prediction. They provide a number of extensive and continually updated knowledge bases and the software needed to interrogate them. Its charitable aims include the sponsorship of activities that advance scientific knowledge and understanding and they regularly support computational chemistry events and initiatives that are of interest to Lhasa Limited members and the wider scientific community. All applications for sponsorship will be considered on their individual merits.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

Consortium for Reliability and Reproducibility

Consortium that has aggregated resting state fMRI (R-fMRI) and diffusion imaging data from laboratories around the world, creating an open science resource for the imaging community, that facilitates the assessment of test-retest reliability and reproducibility for functional and structural connectomics. Given that this was a retrospective data collection, they have focused on basic phenotypic measures that are relatively standard in the neuroimaging field, as well as fundamental for analyses and sample characterization. Their phenotypic key is organized to reflect three classifications of variables: 1) core (i.e., minimal variables required to characterize any dataset), 2) preferred (i.e., variables that were strongly suggested for inclusion due to their relative import and/or likelihood of being collected by most sites), and 3) optional (variables that are data-set specific or only shared by a few sites). CoRR includes 33 datasets consisting of: * 1629 Subjects * 3357 Anatomical Scans * 5093 Resting Functional Scans * 1302 Diffusion Scans * 300 CBF and ASL Scans

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

IAESTE

An independent, non-profit and non-political student exchange organization that provides students in technical degrees (primarily Science, Engineering and the applied arts) with paid, course-related, training abroad and employers with highly skilled, highly motivated trainees, for long or short term projects.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

IBMA toolbox

Image-Based Meta-Analysis toolbox for SPM. Implementation of z-based statistics: Fisher's, Stouffer's.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

EpiTarget

A multidisciplinary project focused on the process leading to epilepsy, epileptogenesis, in adults. Their main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Their central premise and vision is that a combinatorial approach is necessary to identify appropriate biomarkers and develop effective antiepileptogenic therapeutics. The project will focus on: * identifying novel biomarkers and their combinations for epileptogenesis after potentially epileptogenic brain insults in clinically relevant animal models, such as traumatic brain injury (TBI) and status epilepticus (SE); * exploring multiple basic mechanisms of epileptogenesis and their mutual interactions; * and translating these findings towards the clinic by validating biomarkers in human samples accessible to the consortium.

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

sciple.org

SciPle.org uses a two-step data-driven approach to foresee future trends in neuroscience. 1. We build profiles of neuroscientists by collecting interviews with them. 2. These profiles are combined with trends in neuroscience literature to gain insight into the evolution of the "next big thing". SciPle.org merges these two approaches to build an objective model of the neuroscience system, which will allow us to better understand and predict evolving topics and the role played by neuroscientists in shaping and following the current and future trends in neuroscience. We build profiles of neuroscientists by collecting interviews with them: neuroscientists are the agents shaping the neuroscience field. Their interests, drives, motivations and dreams drive their research. Neuroscientists exist in an ecosystem of hidden emergent forces which result from their interactions with thousands of other neuroscientists. Our approach consists in sampling a large pool of neuroscientists. Having a large enough sample (across a reasonable time lag) will allow the building of representative profiles of neuroscientists. * Future: We are aggregating interviews from a large pool of neuroscientists asking them what they envisage for the future of neuroscience. SciPle algorithm will parse those interviews and produce a visualization of the most likely future scenario of the neuroscience field. * Connectivity: We are developing algorithms that will allow profiling of neuroscientists (on the basis of their interviews) and track links (common views on the future and present of neuroscience) between scientists. 1. You send us back SciPle's questionnaire 2. We discover who are the fellows who share the same vision as yours on the future of neuroscience 3. Meet your fellows at conferences and find out whether SciPle was right!

  • Resource
  • SciCrunch
  • 16 years ago - by Anonymous

Astellas Pharma Inc.

Japanese pharmaceutical company formed from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. The company's headquarters are in Tokyo, with research centers in Tsukuba and Osaka. Clinical development is centered in Northbrook, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people. (Wikipedia)

  • Resource
  • SciCrunch
  • 13 years ago - by Anonymous

Alcohol and Alcohol Problems Science Database

Portal to support researchers and practitioners searching for information related to alcohol research including links to a number of databases, journals, and Web sites focused on alcohol research and related topics. Also included is a link to the archived ETOH database, the premier Alcohol and Alcohol Problems Science Database, which contains over 130,000 records and covers the period from 1972 through 2003. Included in ETOH are abstracts and bibliographic references to journal articles, books, dissertation abstracts, conference papers and proceedings, reports and studies, and chapters in edited works. ETOH's scope reflects the multidisciplinary nature of the alcohol research field. The range of subject areas contained in ETOH includes: medicine, biochemistry, psychology, psychiatry, epidemiology, sociology, anthropology, treatment, prevention, education, accidents and safety, legislation, criminal justice, public policy, and health services research. The ETOH database is indexed with vocabulary from the Alcohol and Other Drug Thesaurus: A Guide to Concepts and Terminology in Substance Abuse and Addiction (AOD Thesaurus), Third Edition. More than 5,000 terms in the AOD Thesaurus are used as ETOH descriptors. The Databases/Resources section includes databases and resources for alcohol researchers and practitioners. It includes an introduction to the National Library of Medicine's PubMed and some sample searches on alcohol to run in the PubMed database; descriptions of and links to the various databases of the National Clearinghouse for Alcohol and Drug Information (NCADI); a selection of alcohol and other drug databases with their descriptions and links; links to peer-reviewed journals most often used by alcohol researchers; and links to a selection of Web sites pertinent to the substance abuse field.

  • Resource
  • SciCrunch
  • 17 years ago - by Anonymous

OncoTrack

An international consortium to develop and assess novel approaches to identify and characterize biological markers for colon cancer that will deepen the understanding of the variable make-up of tumors and how this affects the way patients respond to treatment. They will use cutting edge laboratory-based genome sequencing techniques coupled to novel computer modelling approaches to study both the biological heterogeneity of colon cancers (i.e. patient to patient variability) as well as tumor variation within the patient for example, by comparing primary tumors with metastases. This five year project brings together top scientists from European academic institutions offering a wide range of expertise, and partners them with pharmaceutical companies. The project is based on the premise that this genetic and epigenetic information, combined with a description of the molecular pathology of the tumor, will allow OncoTrack to generate a more accurate in-silico model of the cancer cell. This will facilitate the identification of predictive markers that can be used to guide the optimal therapy strategy at the level of the individual patient - and will also provide on-going prognostic guidance for the clinician. This project will not only advance understanding of the fundamental biology of colon cancers but will provide the means and approach for the identification of previously undetected biomarkers not only in the cancer under study, but potentially also in other solid cancers and, in doing so, open the door for personalized management of the oncology patient.


Predict-TB

Consortium to accelerate the search for new, more effective combinations of treatments to tackle Tuberculosis and address pre-clinical research barriers to the discovery and development of new TB drug combinations. To overcome the challenges in Tuberculosis drug development they will create tools to accelerate PK-PD (Pharmacokinetic / Pharmacodynamic) analysis that are connected to clinical outcomes. By addressing the gaps in preclinical information, the consortium aims to provide a framework and tools to facilitate the transition of the best combinations of drugs to late phase development. They aim to develop an integrated set of laboratory-based models that will provide much-needed data to indicate the most appropriate doses and combinations of drugs for patients. In addition, the project will generate a comprehensive database of patient data from previous and on-going clinical trials for use as a reference for evaluating the performance of combination anti-TB drug regimens in these newly developed laboratory models. Ultimately, they aim to enable researchers to be able to use the information generated by the novel models to design better clinical trials involving TB patients. The aims of the consortium: * To systematically evaluate two successive panels of representative anti-tuberculosis drugs (licensed and novel) using a suite of standard, novel and enhanced preclinical model systems, with respect to performance in clinical trials * To refine the set of preclinical systems on the basis of these results in order to identify and define the currently optimal critical path in discovery and pre-clinical development for tuberculosis. * To develop an integrated PK-PD / Disease modelling and simulation framework for tuberculosis which will facilitate prediction of optimal combinations and design of clinical studies.


eTRIKS

Research informatics and analytics platform for the IMI OncoTrack consortium.


University of Connecticut; Connecticut; USA

University of Connecticut is a public land-grant research university system with its main campus in Storrs, Connecticut, United States. It was founded in 1881 as the Storrs Agricultural School, named after two benefactors. In 1893, the school became a public land grant college, then took its current name in 1939.

  • Organization
  • SciCrunch
  • 17 years ago - submitted by Stephen Larson